These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

674 related items for PubMed ID: 20145517

  • 1. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
    Walsh RC, Everly JJ, Brailey P, Rike AH, Arend LJ, Mogilishetty G, Govil A, Roy-Chaudhury P, Alloway RR, Woodle ES.
    Transplantation; 2010 Feb 15; 89(3):277-84. PubMed ID: 20145517
    [Abstract] [Full Text] [Related]

  • 2. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.
    Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, Cardi M, Wadih G, Tevar A, Woodle ES.
    Transplantation; 2008 Dec 27; 86(12):1754-61. PubMed ID: 19104417
    [Abstract] [Full Text] [Related]

  • 3. Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC.
    Pavlakis M.
    Clin Transpl; 2009 Dec 27; ():343-5. PubMed ID: 20524296
    [Abstract] [Full Text] [Related]

  • 4. Abrogation of anti-HLA antibodies via proteasome inhibition.
    Trivedi HL, Terasaki PI, Feroz A, Everly MJ, Vanikar AV, Shankar V, Trivedi VB, Kaneku H, Idica AK, Modi PR, Khemchandani SI, Dave SD.
    Transplantation; 2009 May 27; 87(10):1555-61. PubMed ID: 19461494
    [Abstract] [Full Text] [Related]

  • 5. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.
    Stuckey LJ, Kamoun M, Chan KM.
    Ann Pharmacother; 2012 Jan 27; 46(1):e2. PubMed ID: 22202499
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Proteasome inhibition reduces donor-specific antibody levels.
    Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, Cardi M, Wadih G, Brown E, Tevar A, Woodle ES.
    Transplant Proc; 2009 Jan 27; 41(1):105-7. PubMed ID: 19249489
    [Abstract] [Full Text] [Related]

  • 8. Proteasome inhibition for antibody-mediated rejection.
    Everly JJ, Walsh RC, Alloway RR, Woodle ES.
    Curr Opin Organ Transplant; 2009 Dec 27; 14(6):662-6. PubMed ID: 19667989
    [Abstract] [Full Text] [Related]

  • 9. Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients.
    Govil A, Walsh RC, Tevar A, Alloway R, Roy-Chaudhury P, Mogilishetty G, Wall GE, Brailey P, Girnita A, Woodle ES.
    Clin Transpl; 2009 Dec 27; ():443-53. PubMed ID: 20524313
    [Abstract] [Full Text] [Related]

  • 10. Elimination of post-transplant donor-specific HLA antibodies with bortezomib.
    Idica A, Kaneku H, Everly MJ, Trivedi HL, Feroz A, Vanikar AV, Shankar V, Trivedi VB, Modi PR, Khemchandani SI, Dave SD, Terasaki PI.
    Clin Transpl; 2008 Dec 27; ():229-39. PubMed ID: 19708459
    [Abstract] [Full Text] [Related]

  • 11. Proteasome inhibitor therapy for antibody-mediated rejection.
    Woodle ES, Walsh RC, Alloway RR, Girnita A, Brailey P.
    Pediatr Transplant; 2011 Sep 27; 15(6):548-56. PubMed ID: 21884344
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients.
    Morrow WR, Frazier EA, Mahle WT, Harville TO, Pye SE, Knecht KR, Howard EL, Smith RN, Saylors RL, Garcia X, Jaquiss RD, Woodle ES.
    Transplantation; 2012 Feb 15; 93(3):319-24. PubMed ID: 22179403
    [Abstract] [Full Text] [Related]

  • 14. The fate of anti-HLA antibody among renal transplantation recipients treated with bortezomib.
    Lonze BE, Dagher NN, Simpkins CE, Singer AL, Segev DL, Zachary AA, Montgomery RA.
    Clin Transpl; 2009 Feb 15; ():377-84. PubMed ID: 20524301
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation.
    Sureshkumar KK, Hussain SM, Marcus RJ, Ko TY, Khan AS, Tom K, Vivas CA, Parris G, Jasnosz KM, Thai NL.
    Clin Nephrol; 2012 Mar 15; 77(3):246-53. PubMed ID: 22377258
    [Abstract] [Full Text] [Related]

  • 18. Bortezomib alone fails to decrease donor specific anti-HLA antibodies: 4 case reports.
    Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, Legendre C.
    Clin Transpl; 2009 Mar 15; ():433-8. PubMed ID: 20524311
    [Abstract] [Full Text] [Related]

  • 19. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J, Xue W, Qing X, Jing X, Hou J, Tian X, Guo Q, He X, Cai J.
    Clin Transpl; 2014 Mar 15; ():223-30. PubMed ID: 26281149
    [Abstract] [Full Text] [Related]

  • 20. Antihumoral rejection therapy by proteasome inhibitor bortezomib: a case series.
    Lachmann N, Schütz M, Budde K, Schönemann C, Waiser J.
    Clin Transpl; 2009 Mar 15; ():351-8. PubMed ID: 20527073
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.